Genmark Diagnostics (GNMK) 9.43 $GNMK
GenMark Diagnostics Reports Fourth Quarter and Year End 2013 Results
Business Wire - Tue Mar 11, 3:06PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the fourth quarter and year ended December 31, 2013.
RPE Outsourcing Successfully Completes SOC 1 (SSAE16) Examination for Data Center Security
Business Wire - Fri Feb 28, 7:17AM CST
RPE Outsourcing, LLC (RPEO), a retail cloud computing consultant and IT operations management service provider, has completed a SOC 1 Statement on Standards for Attestation Engagements No. 16 (SSAE 16) Type 2 examination. The completion of the examination typifies RPEO's continued commitment to create and maintain the most stringent controls to ensure the highest quality and security at the company's Data Center. As cloud computing consultants, RPEO offers hosting, Software as a Service and application and operating systems management.
GenMark Diagnostics Schedules Fourth Quarter and Year-End 2013 Financial Results Conference Call for March 11, 2014
Business Wire - Thu Feb 27, 7:35PM CST
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter and year-end earnings results after market close on Tuesday, March 11, 2014. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. EDT on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number "6963720" approximately five minutes prior to the start time.
GenMark Diagnostics to Present at the 34th Annual Cowen Health Care Conference
Business Wire - Wed Feb 26, 6:26PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 34th Annual Cowen Health Care Conference to be held at the Marriott Copley Place Hotel in Boston, MA on Monday, March 3, 2014. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time). The live webcast and audio archive of the presentation will be available at http://ir.genmarkdx.com/events.cfm. A replay of the webcast will be available on the Company's website for approximately 90 days.
GenMark Diagnostics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Tue Jan 07, 12:19PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 32nd Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, CA on Wednesday, January 15, 2014. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). The live webcast and audio archive of the presentation will be available at http://ir.genmarkdx.com/events.cfm. A replay of the webcast will be available on the company's website for approximately 90 days.
Financial Results, Conference Calls Schedules, and Outlook- Research Report on Spectrum, Magellan, Insmed, GenMark, and Envision
PR Newswire - Mon Nov 18, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
5 Stocks Spiking on Unusual Volume
at The Street - Thu Nov 14, 6:37AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
GenMark Diagnostics Reports Third Quarter 2013 Results
Business Wire - Tue Nov 12, 3:02PM CST
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the quarter ended September 30, 2013.
GenMark Diagnostics Schedules Third Quarter 2013 Financial Results Conference Call for November 12, 2013
Business Wire - Tue Oct 29, 5:20PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Tuesday, November 12, 2013. Management will hold a conference call to review the Company's third quarter performance starting at 4:30 p.m. EST on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number "94463692" approximately five minutes prior to the start time.
Hedge Funds Like These 6 Medical Suppliers During Obamacare Rollout
at The Street - Thu Oct 24, 3:58PM CDT
OTC Daily Alert Stock Watch - GenMark Diagnostics, Inc. (NASDAQ: GNMK)
WorldStockWire - Tue Sep 17, 2:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
GenMark Diagnostics Prices Public Offering of Common Stock
Business Wire - Tue Aug 13, 7:45PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering. The size of the offering has been increased and the Company sold 7,622,000 shares of its common stock at a public offering price of $9.84 per share. All of the shares in the offering are being sold by GenMark. The offering is expected to close on August 19, 2013, subject to customary closing conditions.
GenMark to Float New Common Stock Issue
Eric Volkman, The Motley Fool - Motley Fool - Mon Aug 12, 6:29PM CDT
GenMark Diagnostics has come to the conclusion that it needs to widen its equity base. The company announced that it aims to float a $60 million issue of its common stock. Additionally, it intends to grant the issue's underwriter a 30-day option...
GenMark Diagnostics Announces Proposed Public Offering of Common Stock
Business Wire - Mon Aug 12, 3:01PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it intends to commence an underwritten public offering of $60,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by GenMark.
Company News for August 9, 2013 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Aug 09, 7:43AM CDT
Companies in the News are: GNMK,OWW,CSII,APO
GenMark Diagnostics Reports Second Quarter 2013 Results
Business Wire - Wed Aug 07, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the second quarter ended June 30, 2013.
GenMark Diagnostics Schedules Second Quarter 2013 Financial Results Conference Call for August 7, 2013
Business Wire - Mon Jul 29, 6:44PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Wednesday, August 7, 2013. Management will hold a conference call to review the Company's second quarter performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Company's website at www.genmarkdx.com under the investor relations section and will be archived for future reference.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jun 22, 9:12AM CDT
The overall markets experienced the biggest one-day losses in quite a while this week. But those drops were pocket change compared with these horrendous health-care stocks. Delay-related dive Shares of small biotech Idenix Pharmaceuticals took...
Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import
FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston Scientific, Zimmer, St. Jude, ResMed, and GenMark
PR Newswire - Fri Jun 21, 7:00AM CDT
Today, Wall Street Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and GenMark Diagnostics, Inc. (NASDAQ: GNMK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
GenMark Diagnostics Reports Fourth Quarter and Year End 2013 Results
Business Wire - Tue Mar 11, 3:06PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the fourth quarter and year ended December 31, 2013.
RPE Outsourcing Successfully Completes SOC 1 (SSAE16) Examination for Data Center Security
Business Wire - Fri Feb 28, 7:17AM CST
RPE Outsourcing, LLC (RPEO), a retail cloud computing consultant and IT operations management service provider, has completed a SOC 1 Statement on Standards for Attestation Engagements No. 16 (SSAE 16) Type 2 examination. The completion of the examination typifies RPEO's continued commitment to create and maintain the most stringent controls to ensure the highest quality and security at the company's Data Center. As cloud computing consultants, RPEO offers hosting, Software as a Service and application and operating systems management.
GenMark Diagnostics Schedules Fourth Quarter and Year-End 2013 Financial Results Conference Call for March 11, 2014
Business Wire - Thu Feb 27, 7:35PM CST
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter and year-end earnings results after market close on Tuesday, March 11, 2014. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. EDT on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number "6963720" approximately five minutes prior to the start time.
GenMark Diagnostics to Present at the 34th Annual Cowen Health Care Conference
Business Wire - Wed Feb 26, 6:26PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 34th Annual Cowen Health Care Conference to be held at the Marriott Copley Place Hotel in Boston, MA on Monday, March 3, 2014. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time). The live webcast and audio archive of the presentation will be available at http://ir.genmarkdx.com/events.cfm. A replay of the webcast will be available on the Company's website for approximately 90 days.
GenMark Diagnostics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Tue Jan 07, 12:19PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 32nd Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, CA on Wednesday, January 15, 2014. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). The live webcast and audio archive of the presentation will be available at http://ir.genmarkdx.com/events.cfm. A replay of the webcast will be available on the company's website for approximately 90 days.
Financial Results, Conference Calls Schedules, and Outlook- Research Report on Spectrum, Magellan, Insmed, GenMark, and Envision
PR Newswire - Mon Nov 18, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
5 Stocks Spiking on Unusual Volume
at The Street - Thu Nov 14, 6:37AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
GenMark Diagnostics Reports Third Quarter 2013 Results
Business Wire - Tue Nov 12, 3:02PM CST
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the quarter ended September 30, 2013.
GenMark Diagnostics Schedules Third Quarter 2013 Financial Results Conference Call for November 12, 2013
Business Wire - Tue Oct 29, 5:20PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Tuesday, November 12, 2013. Management will hold a conference call to review the Company's third quarter performance starting at 4:30 p.m. EST on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number "94463692" approximately five minutes prior to the start time.
Hedge Funds Like These 6 Medical Suppliers During Obamacare Rollout
at The Street - Thu Oct 24, 3:58PM CDT
OTC Daily Alert Stock Watch - GenMark Diagnostics, Inc. (NASDAQ: GNMK)
WorldStockWire - Tue Sep 17, 2:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
GenMark Diagnostics Prices Public Offering of Common Stock
Business Wire - Tue Aug 13, 7:45PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering. The size of the offering has been increased and the Company sold 7,622,000 shares of its common stock at a public offering price of $9.84 per share. All of the shares in the offering are being sold by GenMark. The offering is expected to close on August 19, 2013, subject to customary closing conditions.
GenMark to Float New Common Stock Issue
Eric Volkman, The Motley Fool - Motley Fool - Mon Aug 12, 6:29PM CDT
GenMark Diagnostics has come to the conclusion that it needs to widen its equity base. The company announced that it aims to float a $60 million issue of its common stock. Additionally, it intends to grant the issue's underwriter a 30-day option...
GenMark Diagnostics Announces Proposed Public Offering of Common Stock
Business Wire - Mon Aug 12, 3:01PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it intends to commence an underwritten public offering of $60,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by GenMark.
Company News for August 9, 2013 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Aug 09, 7:43AM CDT
Companies in the News are: GNMK,OWW,CSII,APO
GenMark Diagnostics Reports Second Quarter 2013 Results
Business Wire - Wed Aug 07, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the second quarter ended June 30, 2013.
GenMark Diagnostics Schedules Second Quarter 2013 Financial Results Conference Call for August 7, 2013
Business Wire - Mon Jul 29, 6:44PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Wednesday, August 7, 2013. Management will hold a conference call to review the Company's second quarter performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Company's website at www.genmarkdx.com under the investor relations section and will be archived for future reference.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jun 22, 9:12AM CDT
The overall markets experienced the biggest one-day losses in quite a while this week. But those drops were pocket change compared with these horrendous health-care stocks. Delay-related dive Shares of small biotech Idenix Pharmaceuticals took...
Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import
FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston Scientific, Zimmer, St. Jude, ResMed, and GenMark
PR Newswire - Fri Jun 21, 7:00AM CDT
Today, Wall Street Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and GenMark Diagnostics, Inc. (NASDAQ: GNMK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
